Brief: Cann Group Enters Into Exclusive Evaluation And Option Agreement With Gsk Consumer Healthcare
April 6 (Reuters) - Cann Group Ltd CAN.AX :
* ENTERED INTO AN EXCLUSIVE EVALUATION AND OPTION AGREEMENT
WITH
GSK CONSUMER HEALTHCARE
* AGREEMENT IN RELATION TO POTENTIAL COMMERCIALISATION OF
CANN'S
SATIPHARM CBD CAPSULES FOR OVER THE COUNTER DISTRIBUTION IN
AUSTRALIA
Further company coverage: CAN.AX
Recent news on Cann
See all newsBrief: Cann Group Posts Q1 Revenue A$3.45 Million
Brief: Cann Group Increases Private Credit Loan Facility By A$2 Million
Brief: Cann Group Says Mike Ryan To Assume Role Of Interim Exec Chair
Brief: Cann Group Anticipates FY2026 Revenue Of A$9.2-A$10 Million
Brief: Cann Group Posts Profit For Half-Year A$26.4 Million